Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/18742
Title: Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.
Authors: Doan, Tan N;Kirkpatrick, Carl M J;Walker, Patricia;Slavin, Monica A;Ananda-Rajah, Michelle R;Morrissey, C Orla;Urbancic, Karen F;Grigg, Andrew P;Spencer, Andrew;Szer, Jeffrey;Seymour, John F;Kong, David C M
Affiliation: Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Melbourne, Victoria, Australia
Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
Department of Clinical Haematology and Bone Marrow Transplant Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Victorian
Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia
The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
University of Melbourne, Melbourne, Victoria, Australia..
General Medicine Unit, Alfred Health, Melbourne, Victoria, Australia
Department of Infectious Diseases, Alfred Health, Melbourne, Victoria, Australia
Department of Infectious Diseases, Monash University, Melbourne, Victoria, Australia
Department of Haematology, Monash University, Melbourne, Victoria, Australia
Pharmacy Department, Austin Health, Heidelberg, Victoria, Australia
Malignant Haematology and Stem Cell Transplantation Service, Alfred Health, Melbourne, Victoria, Australia
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia
Issue Date: Feb-2016
EDate: 2015-10-30
Citation: The Journal of antimicrobial chemotherapy 2016; 71(2): 497-505
Abstract: The primary objectives were to investigate the prescribing practices of primary antifungal prophylaxis (PAP) and incidence of invasive fungal disease (IFD) in adult patients with ALL receiving induction-consolidation chemotherapy. Secondary objectives were to determine risk factors for IFD and resource utilization associated with IFD. A retrospective chart review of adult patients with ALL from commencement of induction until completion of consolidation chemotherapy was undertaken from January 2008 to June 2013 in four hospitals in Melbourne, Australia. IFD was classified according to the revised European Organisation for Research and Treatment of Cancer criteria. Cost analysis was performed from an Australian public hospital perspective. Ninety-eight patients were included in the audit; 83 (85%) received PAP. Most patients (49/83, 59%) switched between two different antifungal agents, predominantly between liposomal amphotericin B and an azole. Five proven/probable and six possible IFD cases were identified. Proven/probable IFD was most common in patients receiving the BFM95 chemotherapy protocol. The incidence of proven/probable IFD was significantly lower in patients receiving PAP compared with those who did not (2/78, 2.6% versus 3/14, 21.4%; P = 0.024). For every five patients receiving PAP, one proven/probable IFD case would be prevented. Proven/probable IFD was associated with an additional median cost of 121,520 Australian dollars (95% CI: 90,781-180,141 Australian dollars; P < 0.001) compared with patients without IFD. This is the first multicentre study evaluating PAP use in patients with ALL. With the caveats of interpretation of retrospective, non-randomized data, PAP was associated with a reduced IFD risk.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18742
DOI: 10.1093/jac/dkv343
PubMed URL: 26518050
Type: Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.